Literature DB >> 19199941

Innate immunity and primary biliary cirrhosis.

Carlo Selmi1, Ana Lleo, Simone Pasini, Massimo Zuin, M Eric Gershwin.   

Abstract

There has been a rapid growth in our understanding of the molecular bases of primary biliary cirrhosis (PBC). These efforts were initiated when the immunodominant mitochondrial autoantigen was cloned and sequenced. Using the recombinant cloned antigen as a tool, research has focused on the effector mechanisms of disease and the uniqueness of the primary target tissue, the intrahepatic bile ducts. Most recently, there have been experimental data suggesting that innate immunity changes may be critical to the initiation and perpetuation of the autoimmune injury, as in the case of the enhanced response of monocytes and memory B cells to infectious stimulation and environmental mimics. These observations are important as they help fill in the many gaps which remain on the most difficult subject of autoimmunity, etiology. Indeed, based on the available data, several experimental models of PBC have been developed. These models illustrate and suggest that PBC can be initiated by several mechanisms, all of which lead to loss of tolerance to the mitochondrial antigens. However, once this adaptive response develops, it appears that much of the subsequent pathology is exacerbated by innate responses. We suggest that future therapeutic efforts in PBC will depend heavily on understanding the nature of this innate immune responses and methodology to blunt their cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199941     DOI: 10.2174/156652409787314525

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  23 in total

1.  T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1.

Authors:  Weici Zhang; Yoko Ono; Yoshinori Miyamura; Christopher L Bowlus; M Eric Gershwin; Emanual Maverakis
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

2.  B cell depletion therapy exacerbates murine primary biliary cirrhosis.

Authors:  Amy Dhirapong; Ana Lleo; Guo-Xiang Yang; Koichi Tsuneyama; Robert Dunn; Marilyn Kehry; Thomas A Packard; John C Cambier; Fu-Tong Liu; Keith Lindor; Ross L Coppel; Aftab A Ansari; M Eric Gershwin
Journal:  Hepatology       Date:  2010-12-28       Impact factor: 17.425

Review 3.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 4.  The immunopathology of human biliary cell epithelium.

Authors:  Ya-Hui Chuang; Ruth Y Lan; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

5.  Immune-mediated bile duct injury: The case of primary biliary cirrhosis.

Authors:  Carlo Selmi; Andrea Affronti; Laura Ferrari; Pietro Invernizzi
Journal:  World J Gastrointest Pathophysiol       Date:  2010-10-15

6.  Gene expression profiles of peripheral blood mononuclear cells in primary biliary cirrhosis.

Authors:  Lei Zhang; Danxu Ma; Xi Li; Chuiwen Deng; Qun Shi; Xin You; Xiaomei Leng; Mengtao Li; Fulin Tang; Fengchun Zhang; Yongzhe Li
Journal:  Clin Exp Med       Date:  2014-11       Impact factor: 3.984

Review 7.  Experimental evidence on the immunopathogenesis of primary biliary cirrhosis.

Authors:  Carlo Selmi; Francesca Meda; Anaid Kasangian; Pietro Invernizzi; Zhigang Tian; Zhexiong Lian; Mauro Podda; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2009-12-23       Impact factor: 11.530

8.  Elevated circulating CD14lowCD16+ monocyte subset in primary biliary cirrhosis correlates with liver injury and promotes Th1 polarization.

Authors:  Anping Peng; Peifeng Ke; Rong Zhao; Xinyi Lu; Cheng Zhang; Xianzhang Huang; Guangjun Tian; Jun Huang; Jinli Wang; Pietro Invernizzi; Qubo Chen; Junhua Zhuang
Journal:  Clin Exp Med       Date:  2015-09-24       Impact factor: 3.984

Review 9.  Primary biliary cholangitis: pathogenesis and therapeutic opportunities.

Authors:  Aliya F Gulamhusein; Gideon M Hirschfield
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-09       Impact factor: 46.802

10.  PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis.

Authors:  Yusuke Nozaki; Kenichi Harada; Takahiro Sanzen; Yasuni Nakanuma
Journal:  Med Mol Morphol       Date:  2013-02-09       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.